De-escalation strategies in the management of differentiated thyroid cancer.

Overdiagnosis and overtreatment of low-risk differentiated thyroid cancer (DTC) have led to a dramatic toward treatment de-escalation. This comprehensive narrative review synthesizes evidence from major trials, cohort studies, and guidelines to outline evidence-based approaches that preserve oncologic safety while minimizing morbidity and healthcare costs. Active surveillance (AS) for papillary thyroid microcarcinoma (PTMC) achieves a 10-year disease-specific survival of 100%, with less than 4% progression to nodal metastasis. For surgically managed low-risk DTC, lobectomy provides equivalent survival to total thyroidectomy but markedly lowers rates of permanent recurrent laryngeal nerve (RLN) injury (0.5% vs. 3.5%). Adjuvant radioactive iodine (RAI) can be safely omitted in low-risk cases, while moderate thyroid-stimulating hormone (TSH) suppression (0.5-2.0 mU/L) minimizes cardiovascular and skeletal risks. Economic analyses further validate the cost-effectiveness of AS and lobectomy, reducing both upfront and lifetime healthcare burdens. Emerging minimally invasive techniques such as radiofrequency and laser ablation show promise as future alternatives. De-escalation guided by clinicopathologic risk and patient preference ensures optimal quality of life without compromising survival, representing a modern, precision-based approach to thyroid cancer management. Continued research and global adoption of these strategies are vital to refine safe, cost-effective, and patient-centered care. De-escalation tailored to clinicopathologic risk and patient preference is safe, effective, and economically favorable for low-risk DTC. Future efforts should focus on expanding the adoption of active surveillance, validating minimally invasive therapies, and refining molecular biomarkers to better distinguish indolent from aggressive disease.